Literature DB >> 30121674

Non-Immune Hydrops, Hypotonia, Encephalopathy, and Liver Failure with Novel Compound Heterozygous AHCY Mutations.

Allison J Judkins1, Brianna C MacQueen2, Robert D Christensen2,3,4, Jessica Comstock5, Rong Mao6, Josue Flores-Daboub7.   

Abstract

A late-preterm infant with a prenatal diagnosis of non-immune hydrops was born with hypotonia, poor respiratory effort, chylothorax, encephalopathy, coagulopathy, progressive hepatic failure, and refractory pulmonary hypertension. Life support was withdrawn at 7 days of life due to multisystem organ failure. Rapid whole exome sequencing revealed novel compound heterozygous mutations in the gene encoding S-adenosylhomocysteine hydrolase (AHCY); each novel variant was carried by an asymptomatic parent. Reports of neonates with other AHCY mutations describe a pathology of varying severity. AHCY mutations should be considered when seeking an etiology for neonates with the combination of non-immune hydrops, hypotonia, encephalopathy, and liver failure.
© 2018 S. Karger AG, Basel.

Entities:  

Keywords:  Autosomal recessive; Chylothorax; Ferritin; Hypotonia; Neonatal liver failure; Non-immune hydrops

Mesh:

Substances:

Year:  2018        PMID: 30121674     DOI: 10.1159/000489292

Source DB:  PubMed          Journal:  Neonatology        ISSN: 1661-7800            Impact factor:   4.035


  3 in total

1.  The biochemical profile and dietary management in S-adenosylhomocysteine hydrolase deficiency.

Authors:  Yue Huang; Richard Chang; Jose E Abdenur
Journal:  Mol Genet Metab Rep       Date:  2022-06-23

Review 2.  Functional and Pathological Roles of AHCY.

Authors:  Pedro Vizán; Luciano Di Croce; Sergi Aranda
Journal:  Front Cell Dev Biol       Date:  2021-03-31

3.  Case Report: Advanced Skeletal Muscle Imaging in S-Adenosylhomocysteine Hydrolase Deficiency and Further Insight Into Muscle Pathology.

Authors:  Danijela Petković Ramadža; Ivana Kuhtić; Kamelija Žarković; Hanns Lochmüller; Mislav Čavka; Ida Kovač; Ivo Barić; Maja Prutki
Journal:  Front Pediatr       Date:  2022-04-08       Impact factor: 3.418

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.